Phase 2 data published in 2023 reported mean body-weight reductions of up to 24.2% at 48 weeks on the highest dose tier (Jastreboff et al., NEJM 2023)
The study, which was published in the journal Endocrine Connections , was called Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? The studys authors suggested that more research will be needed to see if GLP-1 drugs, like Zepbound, may have carcinogenic-like effects in the human body
Can Ozempic Help With Weight-Loss
When people have access to data and support from day one, adherence improves, outcomes strengthen, and care becomes scalable
It can improve body contours as well as self-confidence
This article is meant for informational purposes only and is not medical advice